🟢 Veracyte is trading 4.32% up in pre-market, with Decipher findings in focus

Veracyte is trading at $50.00, up 4.32% in pre-market on October 26; Decipher data is a plausible company-specific catalyst, though a direct link to the move is unconfirmed. - Veracyte closed at $47.93 on October 23. - Announced October 23, Phase III STAMPEDE findings showed Decipher predicted which very high-risk patients benefited from adding abiraterone to treatment. The analysis covered 401 patients and was presented at ESMO on October 24. - Q3 results are scheduled for November 4.